Clinical Trial Update: CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating CDK4/6 inhibitors combined with endocrine therapy for hormone receptor-positive breast cancer; the study is not yet re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• High-risk Breast Cancer
• Hormone Receptor-positive Breast Cancer

Snippet

Sponsor: Peking University People's Hospital | Conditions: Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING